Somewhat Positive Media Coverage Somewhat Unlikely to Affect Clearside Biomedical (CLSD) Stock Price
Headlines about Clearside Biomedical (NASDAQ:CLSD) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Clearside Biomedical earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.4975161325952 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Clearside Biomedical (NASDAQ CLSD) traded down $0.21 during trading hours on Friday, reaching $6.34. The company’s stock had a trading volume of 130,485 shares, compared to its average volume of 164,729. The stock has a market capitalization of $155.52 and a PE ratio of -3.30. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.57 and a quick ratio of 4.57. Clearside Biomedical has a fifty-two week low of $5.44 and a fifty-two week high of $10.46.
Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.17). Clearside Biomedical had a negative return on equity of 90.72% and a negative net margin of 17,684.07%. The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.01 million. equities analysts forecast that Clearside Biomedical will post -2.37 earnings per share for the current year.
Several research analysts have issued reports on CLSD shares. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. Cowen reissued a “buy” rating on shares of Clearside Biomedical in a research report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $18.33.
In other news, Director Clay Thorp sold 35,000 shares of the firm’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $8.57, for a total value of $299,950.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Daniel H. White sold 8,000 shares of the firm’s stock in a transaction dated Thursday, October 19th. The stock was sold at an average price of $7.82, for a total value of $62,560.00. Following the completion of the transaction, the insider now directly owns 477,935 shares in the company, valued at approximately $3,737,451.70. The disclosure for this sale can be found here. Insiders sold 113,000 shares of company stock worth $839,010 in the last ninety days. Corporate insiders own 20.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/12/24/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-clearside-biomedical-clsd-stock-price.html.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.